Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 8, 2015, Pages

  Lo, Clement ^a   Toyama, Tadashi ^b   Hirakawa, Yoichiro ^b   Jun, Min ^b   Cass, Alan ^c   Hawley, Carmel ^d   Pilmore, Helen ^e   Badve, Sunil V ^d   Perkovic, Vlado ^b   Zoungas, Sophia ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

^c MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^d PRINCESS ALEXANDRA HOSPITAL   (Australia)

^e AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; AMYLIN DERIVATIVE; BROMOCRIPTINE; CHOLESTEROL; CREATININE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; TRIACYLGLYCEROL;

ALL CAUSE MORTALITY; ARTICLE; BODY WEIGHT; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; ESTIMATED GLOMERULAR FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEART DEATH; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; LIPOPROTEIN BLOOD LEVEL; PRIORITY JOURNAL; RETINOPATHY; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 85013882661     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD011798     Document Type: Article

References (43)

1. American Diabetes Association. Standards of medical care in diabetes--2012. Diabetes Care 2012;35 Suppl 1:S11-63. [MEDLINE: 22187469]
2. American Diabetes Association. Standards of medical care in diabetes--2014. Diabetes Care 2014;37 Suppl 1:S14-80. [MEDLINE: 24357209]
3. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England Journal of Medicine 2008;358(24):2560-72. [MEDLINE: 18539916]
4. Chadban SJ, Briganti EM, Kerr PG, Dunstan DW, Welborn, TA, et al. Prevalence of kidney damage in Australian adults: The AusDiab kidney study. Journal of the American Society of Nephrology 2003;14(7 Suppl 2):S131-8. [MEDLINE: 12819318]
5. Chadban S, Howell M, Twigg S, Thomas M, Jerums G, Cass A, et al. Prevention and management of chronic kidney disease in type 2 diabetes. Nephrology 2010;15 Suppl 1:S162-94. [MEDLINE: 20591029]
6. Collins AJ, Kasiske B, Herzog C, Chavers B, Foley R, Gilbertson D, et al. Excerpts from the United States Renal Data System 2006 Annual Data Report. American Journal of Kidney Diseases 2007;49(1 Suppl 1):A6-7, S6-296. [MEDLINE: 17189040]
7. Collins AJ, Foley R, Herzog C, Chavers B, Gilbertson D, Ishani A, et al. Excerpts from the United States Renal Data System 2007 Annual Data Report. American Journal of Kidney Diseases 2008;51(1 Suppl 1):S1-320. [MEDLINE: 18086389]
8. Control Group, Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009;52(11):2288-98. [MEDLINE: 19655124]
9. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. American Journal of Kidney Diseases 2003;41(1):1-12. [MEDLINE: 12500213]
10. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. New England Journal of Medicine 1993;329(14):977-86. [MEDLINE: 8366922]
11. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney International 1995;47(6):1703-20. [MEDLINE: 7643540]
12. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. New England Journal of Medicine 2009;360(2):129-39. [MEDLINE: 19092145]
13. Feldt-Rasmussen B. Is there a need to optimize glycemic control in hemodialyzed diabetic patients?. Kidney International 2006;70(8):1392-4. [MEDLINE: 17024163]
14. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. [MEDLINE: 12958120]
15. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
16. Holman R, Paul SK, Bethel A, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine 2008;359(15):1577-89. [MEDLINE: 18784090]
17. International Diabetes Federation. IDF Diabetes Atlas. 6th edition. 2013. /www.idf.org/sites/default/files/EN_6E_Atlas_Full_0.pdf (accessed 6 July 2015).
18. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55(6):1577-96. [MEDLINE: 22526604]
19. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010;376(9739):419-30. [MEDLINE: 20594588]
20. Jackson MA, Holland MR, Nicholas J, Lodwick R, Forster D, Macdonald IA. Hemodialysis-induced hypoglycemia in diabetic patients. Clinical Nephrology 2000;54(1):30-4. [MEDLINE: 10939754]
21. Jun M, Lo C, Badve SV, Pilmore H, White SL, Hawley C, et al. Glucose lowering therapies for chronic kidney disease and kidney transplantation. Cochrane Database of Systematic Reviews 2012, Issue 8. [DOI: 10.1002/14651858.CD009966]
22. Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney International 2011;80(1):17-28. [MEDLINE: 21150873]
23. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. American Journal of Kidney Diseases 2002;39(2 Suppl 1):S1-266. [MEDLINE: 11904577]
24. National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. American Journal of Kidney Diseases 2012;60(5):850-86. [MEDLINE: 23067652]
25. Kobayashi S, Maejima S, Ikeda T, Nagase M. Impact of dialysis therapy on insulin resistance in end-stage renal disease: comparison of haemodialysis and continuous ambulatory peritoneal dialysis. Nephrology Dialysis Transplantation 2000;15(1):65-70. [MEDLINE: 10607769]
26. Levin SR, Coburn JW, Abraira C, Henderson WG, Colwell JA, Emanuele NV, et al. Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators. Diabetes Care 2000;23(10):1478-85. [MEDLINE: 11023140]
27. Loipl J, Schmekal B, Biesenbach G. Long-term impact of chronic hemodialysis on glycemic control and serum lipids in insulin-treated type 2 diabetic patients. Renal Failure 2005;27(3):305-8. [MEDLINE: 15957547]
28. McDonald S, Excell L, Dent H. ANZDATA 32nd Annual Report. 2009 Report: Data to 2008. Chapter 2: New patients commencing treatment in 2008. www.anzdata.org.au/anzdata/AnzdataReport/32ndReport/Ch02.pdf (accessed 6 July 2015).
29. Moen MF, Zhan M, Hsu VD, Walker LD, Einhorn LM. Seliger SL, et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clinical Journal of the American Society of Nephrology: CJASN 2009;4(6):1121-7. [MEDLINE: 19423569]
30. Moghissi ES, Korytkowski MT, DiNardo M, Einhorn D, Hellman R, Hirsch IB, et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care 2009;32(6):1119-31. [PUBMED: 19429873]
31. Morioka T, Emoto M, Tabata T, Shoji T, Tahara H, Kishimoto H, et al. Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care 2001;24(5):909-13. [MEDLINE: 11347753]
32. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. New England Journal of Medicine 2005;353(25):2643-53. [MEDLINE: 16371630]
33. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Research & Clinical Practice 1995;28(2):103-17. [MEDLINE: 7587918]
34. Oomichi T, Emoto M, Tabata T, Morioka T, Tsujimoto Y, Tahara H, et al. Impact of glycemic control on survival of diabetic patients on chronic regular hemodialysis: a 7-year observational study. Diabetes Care 2006;29(7):1496-500. [MEDLINE: 16801568]
35. Perkovic V, Ninomiya T, Arima H, Gallagher M, Jardine M, Cass A, et al. Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: Data from the PROGRESS Study. Journal of the American Society of Nephrology 2007;18(10):2766-72. [MEDLINE: 17804673]
36. Perkovic V, Heerspink HL, Chalmers J, Woodward M, Jun M, Li Q, et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney International 2013;83(3):517-23. [MEDLINE: 23302714]
37. Radbill B, Murphy B, LeRoith D. Rationale and strategies for early detection and management of diabetic kidney disease. Mayo Clinic Proceedings 2008;83(12):1373-81. [MEDLINE: 19046557]
38. Shurraw S, Majumdar SR, Thadhani R, Wiebe N, Tonelli M. Glycemic control and the risk of death in 1, 484 patients receiving maintenance hemodialysis. American Journal of Kidney Diseases 2010;55(5):875-84. [MEDLINE: 20346561]
39. Shurraw S, Hemmelgarn B, Lin M, Majumdar SR, Klarenbach S, Manns B, et al. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Archives of Internal Medicine 2011;171(21):1920-6. [MEDLINE: 22123800]
40. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352(9131):857-53. [MEDLINE: 9742976]
41. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352(9131):854-65. [MEDLINE: 9742977]
42. Williams ME, Lacson EJ Jr, Teng M, Ofsthun N, Lazarus JM. Hemodialyzed type I and type II diabetic patients in the US: characteristics, glycemic control, and survival. Kidney International 2006;70(8):1503-9. [MEDLINE: 16941022]
43. Wu MS, Yu CC, Yang CW, Wu CH, Haung JY, Hong JJ, et al. Poor pre-dialysis glycaemic control is a predictor of mortality in type II diabetic patients on maintenance haemodialysis. Nephrology Dialysis Transplantation 1997;12(10):2105-10. [MEDLINE: 9351073]